Portal sees surge in traffic see more
In early March, Thornton Kirby, president and CEO of the S.C. Hospital Association, raised an alarm that South Carolina may face a shortage of personal protective equipment.
The message circulated through a number of economic development groups, along with surveys probing retooling capabilities in response to the Trump administration’s invocation of the Defense Production Act.
As manufacturers geared up across the state to meet critical needs, the S.C. Hospital Association, SCBio, the S.C. Department of Commerce and the S.C. Manufacturing Extension Partnership joined forces to connect healthcare providers and other industries with critical needs equipment through the S.C. Emergency Supply Collaborative portal announced April 13.
Kirby said the portal will help streamline the product’s trip from the manufacturer to the hospital. He hopes other sectors, such as auto assembly, construction and education, will be able to make use of the portal to replenish their equipment stores, too.
“There are some who are on a two-, three-, four-day supply but generally, we’re better than we were a couple weeks ago. The problem is that assumes the current number of COVID patients. If you fill up a hospital with 50 or 60 more like they do in New York City, the so-called ‘burn rate’ for every patient goes up a lot,” Kirby said on April 13.
He hopes the mobilization of manufacturers across the state will also contribute to a state stockpile for future emergencies.
“The national stockpile has been largely distributed, at least to the best of my understanding. South Carolina did get our share, that’s 1% based on population, but the volume of personal protective equipment is just so great, it quickly outstripped the national stockpile,” he said.
Chuck Spangler, CEO and president of the S.C. Manufacturing Extension Partnership, said he was awake until midnight after the announcement of the portal, responding to S.C. manufacturers who want to sell their critical needs goods through the portal.
“It’s been a thrill to see all of these companies step up, rise to the challenge and meet the critical needs in our state,” Spangler said.
By Tuesday morning, Spangler said about 80 companies had joined the portal to sell critical needs goods after careful vetting from portal organizers to bar price-gougers. Several offered donations.
“Last week, we saw an incredible response,” he said.
About 15 health care providers had already begun scouting out the portal for PPE and other equipment along with several manufacturers.
As many of the state’s manufacturers return to normal operations — Spangler thinks by May 4 — he hopes South Carolina will support each other by buying and selling PPE through the portal and is encouraging manufacturers to consider using other three-layer mask alternatives to preserve the stores of N95 masks for health care workers and food providers.
Courtesy: GSA Business Report
SCBIO believes growing the life sciences sector will significantly transform the state’s economy. see more
Compliments of the Community Journal...
It was all smiles on Sept. 30 as BMW marked the 25th anniversary of the first vehicle to roll off its Spartanburg assembly line, a singular moment that dramatically transformed the economic face of South Carolina.
A quarter-century after opening, the German manufacturer’s North American facility employs more than 11,000 workers who build 1,500 vehicles daily, a pace requiring the services of more than 40 main suppliers across the state.
The average wage among all S.C. jobs supported by the automotive industry stood at $64,120 in 2017 compared to $40,293 across all employment categories, say findings commissioned by the South Carolina Biotechnology Industry Organization (SCBIO).
Now three years old, SCBIO is spearheading an aggressive initiative to make South Carolina the preferred location for new or expanding companies in another highly promising industry: life sciences. Read the entire story by clicking here.
Enjoy this week's Monday Moment from SC Life Sciences see more
SCBIO's latest Monday Moment arrives amidst the COVID-19 storm to provide meaningful and inspiring information in 3 minutes or less. This week, enjoy an uplifting reminder from Will Williams, President & CEO of the Economic Development Partnership... plus lots of uplifting news... get details here
Mike Briggs of Central SC Alliance passes away from cancer see more
Earlier this week, South Carolina life sciences and our state in general lost one of its great economic development champions. Mike Briggs, former president and CEO of the Central SC Alliance, passed away following a valiant battle with cancer.
Mike began what would become a two-plus decade tenure with the Central SC Alliance in 1997, just three years after the organization’s inception. Alongside the organization’s members and stakeholders, he worked tirelessly in the collaborative regional effort to attract and grow industry within Central SC’s footprint. His participation and early adoption of statewide marketing initiatives helped expand the voice of the region and South Carolina, both domestically and globally. He was a strong champion of and friend to South Carolina's life sciences community as well.
Known for warm welcomes and unmatched hospitality, Mike was recognized as a trailblazer in economic development. And while success was important, he always kept family in focus and was quick to inquire about significant life events (weddings, babies and the like). He retired this June after 23 years of service.
Mike was a longtime friend and colleague to many in South Carolina’s business community, and he leaves a lasting legacy. The life sciences community and SCBIO extend our sincere condolences to the Briggs family.
Veravas partners to develop test see more
True Diagnostics, Inc. (TrueDx), a leading Point of Care (POC) company, Infectolab Americas (Infectolab), a recently established CLIA laboratory specializing in comprehensive testing for tick-born infection, and Veravas, Inc. (Veravas), an emerging diagnostic company focusing on proprietary sample preparation products and new diagnostic tests, announced today their Strategic Alliance to develop and commercialize VeraTest™ SARS-CoV-2 IgA/IgG Rapid Test. This novel POC test will utilize the TrueDX Platform™, Infectolab's COVID-19 serology testing services and infectious disease expertise,and Veravas' patent pending VeraPrep™ clean and VeraPrep™ capture technologies to remove cross-reacting antibodies to other coronaviruses while only binding and detecting antibodies specific to SARS-CoV-2. Serology testing makes population screening possible, including screening of people who were never diagnosed, either because they didn't feel particularly sick or they couldn't get an initial test. VeraTest™ SARS-CoV-2 IgA/IgG Rapid Test will play an important roll in understanding COVID-19 and the epidemiology of this coronavirus.
VeraTest™ SARS-CoV-2 IgA/IgG Rapid Test will provide a digital qualitative answer in less than 15 minutes to determine if antibodies against COVID-19 have been detected in the blood. IgM and IgA provide the first line of defense during viral infections, followed by the generation of adaptive, high-affinity IgG responses for long-term immunity and immunological memory. The detection of COVID-19 IgA antibodies tends to indicate a recent exposure to COVID-19 and is more specific for COVID-19 in lung tissues and mucosal surfaces, and detection of COVID-19 IgG antibodies indicates a later stage of infection, so this combined antibody test could also provide information on the stage of the disease in patients. Current guidance from the U.S. Food and Drug Administration (FDA) recommends that results from antibody testing should not be used as the sole basis to diagnose or exclude coronavirus infection. Depending on the clinical scenario, additional testing, such as with VeraTest™ COVID-19 IgA/IgG Rapid Test, may be considered to further evaluate the possibility of SARS-CoV-2 infection.
"In these challenging times, True Diagnostics, Inc. is proud to be part of this alliance to help expedite critical solutions that can help provide the needed specificity, performance, scalability, and simplicity to market," stated Jerry Lee, CEO and President of True Diagnostics. "Veravas is quickly emerging as the leader in raising the standard of care in laboratory medicine and we look forward to co-developing tools that are essential to support the IVD market and improving the lives of so many patients."
"A collaboration between Infectolab Americas and Veravas is the logical consequence for our two Minnesota companies. We are complementary to each other and have a lot of synergy. We will use this to achieve something that is desperately needed in this time of testing crisis. We will strive to deliver a high quality test for SARS-CoV-2 that is more accurate and sensitive than any other test on the market," said Felix Scholz, President of Infectolab Americas.
"This strategic alliance with TrueDx utilizing their TrueDX Platform™, along with Infectolab's CLIA lab validation capabilities and infectious disease expertise, will allow Veravas to quickly develop a POC test that's easy to use and displays results in under 15 minutes. We are confident that the combined efforts of our three companies will result in the successful development of a rapid test that will assist healthcare providers and laboratorians to quickly and reliably determine whether a patient has developed antibodies to the COVID-19 virus. Most importantly, it will identify those individuals who can safely return to work and go about their daily lives," said Carroll E. Streetman Jr., Chief Executive Officer of Veravas.
TrueDx and Veravas continue to collaborate and expand their portfolios with other emerging organizations and institutions to bring diagnostic solutions and products like VeraTest™ to market.
About True Diagnostics
True Diagnostics (TrueDx) designs and develops innovative POC diagnostic tests and devices based on its proprietary TrueDX™ Platform, which utilizes reliable and low-cost lab methods and its own proprietary or partnered biomarkers to offer rapid diagnoses to facilitate treatment decisions in point-of-care, point-of-incidence and remote-of-care settings. The TrueDX Platform's portability and affordability allow it to be easily adopted into emerging markets to provide accurate diagnosis within minutes. For the $21 billion point-of-care market, the power of the TrueDX Platform lies in its simplicity and flexibility. Tests have an 18-month or longer shelf life with no refrigeration required. The platform's flexible design additionally permits it to quickly commercialize a myriad of biomarkers discovered for cancer, autism, Alzheimer's, diabetes, drugs of abuse, infectious diseases, cardiac health, traumatic brain injury, viral and bacterial infections and more.
About Infectolab Americas
Infectolab Americas is a recently established laboratory located in Oakdale, Minnesota, specializing in comprehensive lab testing for tick-borne infections which provides the tools necessary for Health Care Practitioners to diagnose tick-borne diseases. Their focus is on delivering a quality laboratory performance and guaranteeing a superior sample output; this entails quick shipping time and a rapid turnaround time, as well as providing the most accurate laboratory results possible.
Veravas is transforming laboratory medicine with technology that delivers superior test results, providing confidence to clinicians and patients that diagnoses are accurate. The company's R&D facilities are based in Oakdale, Minnesota, and our staff of scientists and business development are rapidly driving the commercialization of proprietary sample preparation products and new diagnostic tests. Veravas' nanomagnetic particles can identify, remove, and measure select substances from patient samples to reduce the effects of complex interferences and detect low-abundance biomarkers. Led by a passionate and dedicated team, Veravas is devoted to improving patient lives by minimizing the harmful effects of unnecessary treatments and deaths associated with poor quality diagnostic results. Because every patient deserves the correct result, every time. Please visit us at www.veravas.com
AVX stepping up to fight COVID-19 crisis see more
To meet the rapid increase in customer demand for critical medical equipment such as lung ventilators, mobile x-ray, CT systems, ultrasound, and patient monitors, AVX is preparing its plants to actively support the manufacture of all required components to produce the medical equipment needed to prevent the further spread of the COVID-19 virus and treat those who have been infected.
AVX provides a wide range of components that are critical to medical electronics in general and specifically ventilators. AVX NTCs measure gas and patient temperature. Tantalum and ceramic capacitors as well as Schottky diodes are used throughout the power supply system that powers the pumps, motors, displays, and control logic in ventilators. TransGuards are used as transient voltage protection on interfaces, keyboards, touch screens and audio alarms.
AVX provides a wide range of components that are critical to medical electronics in general and specifically ventilators. (Credit: AVX)
“All of us, at every level, function and business, feel the significance and the intensity surrounding the worldwide COVID-19 pandemic situation, both in our personal and professional lives. Teams across the company have been meeting daily to address critical employee and customer issues. What motivates AVX every day is knowing that despite the current situation, we are rising to the challenge as our manufacturing plants continue to deliver for our customers around the globe,” the company notes.
In a recent example, AVX has committed to fast delivery of high-grade tantalum capacitors from its plant in Lanskroun, Czech Republic, directly to UK Smith Medical company in urgent need for building 10,000 ventilators for hospitals and healthcare institutions. The requirement for three TRJ series part types were processed with top urgency to deliver it in the shortest term while keeping its high-quality standard.
According to the company, the plants continue to give their best effort to deliver all parts as soon as possible, with the shortest possible lead times with a focus on functioning effectively and efficiently to minimize all delays.
SCBIO's latest newsletter is full of the news you need see more
This week's SCBIO newsletter is chock full of helpful news and resources to assist you in navigating the COVID-19 pandemic. Learn about the just-launched Emergency Supply Portal... a job board for hiring displaced workers... mini-profiles on how SC companies are stepping up... the latest news, big savings and much more. Click here to read in full right now!
Gain inspiration from today Monday Moment from SCBIO see more
SCBIO's latest Monday Moment arrives amidst the COVID-19 storm to provide meaningful and inspiring information in 2 minutes or less. This week, enjoy an uplifting reminder from Womble Bond Dickinson's Stephanie Few that we're all in this together, plus helpful webinars, news on how SC is stepping up, and more good news to kickstart your day...
Zylo nominated to BIO contest see more
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced that it has been nominated as a finalist for the Buzz of BIO Contest, which recognizes the most innovative companies in the life sciences.
BIO is the world’s largest biotech association. Among other conferences, the association sponsors the 2020 BIO International Convention each year, with almost 20,000 attendees. It takes place in San Diego this year in June, where the winner of Buzz of BIO will be announced.
Each finalist was asked to submit the three compelling reasons to vote for them. Zylö’s reasons are summarized as follows:
1. Zylö’s endocannabinoid-loaded Z-pod™ solution is showing striking results in a lupus model... Lupus affects women and people of color disproportionately and has tragic quality-of-life ramifications.
2. Our nitric-oxide-releasing Z-pod™ topical solution is showing compelling results in an Erectile Dysfunction model (where ED is secondary to prostatectomy, a condition that is not treatable with Viagra et al.); this solution should translate well as a treatment for older women with sexual dysfunction.
3. Our technology is disruptive and affordable... and we plan on keeping it that way.
Scott Pancoast, Zylö CEO and founder, stated “This is a huge honor and reflects the incredible innovation taking place in our lab from Andrew Draganski PhD, scientific founder, and scientists Eric Renne (M.S., U.C.) and Clay Tucker (M.S., Clemson). We encourage folks in the Upstate to vote in an effort to continue this region’s winning ways in the world of technological innovation.”
About Zylö Therapeutics: Zylö has developed a breakthrough topical delivery system that extends the duration-of-effect, improves the solubility/targeting, and/or enhances the product performance of many therapeutic agents. Notably, the Z-pod™ technology platform has enabled the Patchless Patch™ concept and has successfully harnessed the therapeutic potential of nitric oxide, one of the most powerful—and short-lived—biomolecules produced by our bodies. For more details please visit our web site, www.zylotherapeutics.com and follow us on Twitter (@ZyloTherapies).
SC Life Sciences has a new portal for coronavirus information, courtesy of SCBIO see more
Your SCBIO team is monitoring the most up-to-date safety, infection control and health protocols recommended by global experts, including the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), South Carolina DHEC and others. We've organized the information, updated daily, on the new Coronavirus page here.
The team is also deploying new ways to keep South Carolina's life sciences industry connected and informed. New weekly webinars start Friday at 10am, sharing resources and relevant news right from the mouths of life sciences leaders in our state and nationally.
Check out the full spectrum of news here, and send us your ideas and updates on how you and your organization are faring, and making a difference, in this critical battle. We care.
Spartanburg Regional's Gibbs Cancer Center to open expanded facility see more
With a seven-story, $72 million expansion set to open on March 16, Spartanburg Regional Healthcare System’s Gibbs Cancer Center plans to offer patients treatment beyond traditional chemotherapy and radiation.
At a ribbon-cutting held Thursday, staff unveiled the 191,000-square-foot expansion. The center includes a new physical therapy gym, patient accessible-kitchen, retail shop featuring wigs and prosthesis-fitting services and an on-site outpatient pharmacy. The facility offers radiation, medical and surgical oncology along with cyber knife technologies, centralized lab services, genetic counseling and an integrative medicine center.
“We’re blessed in the Upstate to have a world-class cancer center here that enables patients not to have to travel far,” said Tony Kouskolekas, Pelham Medical Center’s president. “They are able to get first-quality opinions and recommendations on cancer care, and what makes us a little different is that our doctors are committed to what we call multi-disciplinary care. Historically, they have gotten together to discuss someone’s case once someone was diagnosed with cancer. Now, the design of this building will allow them to come together while patients are in the building for multidisciplinary clinics, so that patients can get opinions from multiple providers while they are here for one visit.”
Kouskolekas expects that the center will bring 80 jobs to the area in its first stages, but notes that there is plenty of room to grow as needed.
“To be involved with the planning of this and working with our cancer team has just been another great facet, Kouskolekas said. “Our campus is poised for growth: we have plenty of land and so if we need to do something, we certainly can.”
According to Dr. Michael Starnes, Gibbs Cancer Center’s radiation oncology director, 36 exam rooms have been reserved for the March 16 opening, bringing the center to 75% capacity. Starnes said the center prioritizes clinical research and holistic care alongside traditional treatment measures. The integrative medicine center will allow patients a bridge to recovery through massage and art therapy, tai chi and cooking classes recorded for outpatient survivors to follow.
The new space raises the center’s capacity from less than 10 infusion treatment beds to 40 treatment rooms.
Dr. Heather Allen, a radiology oncologist at Gibbs Cancer Center, noted that the new facility streamlines and strengthens collaborative treatment opportunities spearheaded by oncologists Drs. James Bearden and Julian Josey when they founded the Gibbs Cancer Center 40 years ago.
“They were ahead of the game. This is the model that works, but it wasn’t in place 40 years ago. It was their vision to take a new paradigm shift in cancer treatment and bring it home to the local area,” Allen said.
Prisma Health acquires two hospitals in South Carolina see more
Prisma Health-Midlands will acquire two Midlands health systems through an agreement announced Thursday. The 1.2 million-patient healthcare provider, headquartered in Greenville, has
purchased LifePoint Health’s Camden-based KershawHealth and Columbia’s Providence Health systems with plans to extend its Midlands network.
“We are delighted at the prospect of welcoming the Providence and KershawHealth teams to the Prisma Health family,” Mark O’Halla, president and chief executive officer of Prisma Health, said in a news release. “Providence and KershawHealth are known to share our commitment to improving patient experiences, clinical quality and access to care. We look forward to continuing our mutual goal of enhancing the health of our communities.”
Terms of the acquisition were not disclosed.
Through integration of KershawHealth and Providence Health, Prisma Health plans to target clinical expansion in areas including pediatric, orthopedic, women’s health and cardiovascular care, according to the release.
Providence Health will bring two hospitals, a freestanding emergency room, sleep centers, cardiac rehab facilities, outpatient therapy centers and a number of network practices into Prisma’s fold, the release said. Kershaw Health serves four cities through its Camden medical center, Elgin outpatient and urgent care center, West Wateree Medical Complex, sleep diagnostics center and therapy facility, now operated by Prisma Health.
“Ensuring that we maintain access to healthcare in South Carolina’s rural communities has been a priority of my administration, but we’ve always known that the private sector would be our most important partners in reaching that goal,” Gov. Henry McMaster said in the release. “This proposed acquisition would provide new opportunities to enhance clinical quality and improve access to affordable care for patients in the Midlands and beyond, but it also shows that Prisma Health is committed to the communities it serves, and for that, we should all be grateful.”
Source: GSA Business Report
Husman launches new quality and compliance consultancy see more
Dr. David Husman has launched David Husman Consulting, LLC, a company that assists manufacturers with quality and compliance within the pharmaceutical, biopharmaceutical, and biotech industries. Services include quality program development, compliance auditing, remediation, and training.
Serving as president and principal consultant of the company, Dr. Husman holds a doctorate degree in biochemistry and has more than 30 years of diverse international experience in quality assurance, quality control, and regulatory affairs within the pharmaceutical, biopharmaceutical, and biotech industries. Before beginning David Husman Consulting, he was a principal consultant with Parexel Consulting. He also has served previously in leadership roles in quality assurance, quality control, and regulatory affairs.
Dr. Husman is certified in Good Manufacturing Practices and regulatory affairs. He earned his doctorate and bachelor’s degree in biochemistry from The Ohio State University in Columbus, Ohio. He is a long-term member of various professional organizations, including the Regulatory Affairs Professional Society, Parenteral Drug Association, American Society for Quality, and the S.C. Biotechnology Innovation Organization.
David Husman Consulting began accepting clients as of February 1, 2020. For more information, visit DavidHusmanConsulting.com.
Nephron's Lou Kennedy appointed by Governbor to SCRA Executive Committee see more
SCRA, a public, nonprofit corporation chartered to grow South Carolina’s innovation economy and foster job creation, announced the appointment by Gov. Henry McMaster of Lou Kennedy to the SCRA Board of Trustees’ Executive Committee.
The nine-member group is comprised of the presidents of Clemson University, the Medical University of South Carolina and the University of South Carolina, the governor or designee (to serve as Chairman), an additional appointee of the governor, the chairman of the House Ways and Means Committee or designee, the chairman of the Senate Finance Committee or designee and two additional members.
Ms. Kennedy is the president, CEO and owner of Nephron Pharmaceuticals Corporation, a woman-owned business that leads the world in the manufacturing of generic respiratory medications. Kennedy received her Bachelor of Arts in Public Relations from the University of South Carolina. She has received numerous awards in South Carolina and across the country for her achievements in business and leadership. Kennedy is also the immediate past chairman of the S.C. Chamber of Commerce and chairman of the Board of Directors of SCBIO, the state's official life sciences organization.
“I am excited to welcome Ms. Kennedy to SCRA’s Executive Committee,” said Don Herriott, chairman of the SCRA Board. “Her extensive business and leadership experience has had a tremendous positive impact on South Carolina and makes her a valuable addition to the governing body of SCRA.”
GGC Partnership Campus website to market for future growth see more
Courtesy of GSA Biz Wire
The Greenwood Genetic Center (GGC) Foundation, a nonprofit 501c3 established to serve as the philanthropic arm supporting the mission of the Greenwood Genetic Center, is proud to announce the launch of a new website highlighting their GGC Partnership Campus at http://partnershipcampus.com/.
The GGC Partnership Campus will serve as both an anchor of Greenwood’s emerging Medical Innovation District and as a vital, connected hub within the broader Greenwood community. The campus will become the location of choice for companies and organizations seeking a quality-of-life environment with a focus on promoting connections and collaboration.
The GGC Partnership Campus will provide a unique asset for the City of Greenwood while supporting GGC’s long-term goals for the delivery of clinical care, diagnostic testing, research advances, and educational initiatives.
In addition to the Greenwood Genetic Center, the campus currently includes The Upper Savannah Council of Governments, Carolina Health Center’s Children's Center, and the Clemson Center for Human Genetics’ Self Regional Hall.
The Clemson Center for Human Genetics’ (CCHG) presence on the campus enables Clemson’s growing genetics program to collaborate closely with the tradition of excellence in genetic services, testing, and research at GGC, combining basic science with clinical care. Last year, CCHG named internationally acclaimed geneticist, Dr. Trudy Mackay, as Director of CCHG. Dr. Mackay is building a team of researchers to advance the understanding of the fundamental principles by which genetic and environmental factors determine and predict both healthy traits and susceptibility to disease in humans. Together, the CCHG and GGC will strive to use new technologies and knowledge to develop treatments for genetic disorders.
The GGC Partnership Campus website features a streamlined modern design, improved functionality, and easy access to essential information to help individuals and companies looking to locate on the GGC Partnership Campus. The new comprehensive website offers campus information, relocation assistance, a facilities overview, news, and contact information.
About The Greenwood Genetic Center Foundation
The GGC Foundation is a nonprofit 501c3 established to serve as the philanthropic arm supporting the Greenwood Genetic Center (GGC) in their work of serving families in the fight against genetic diseases, birth defects and autism. GGC has provided over 45 years of compassionate clinical care, unparalleled diagnostic lab services, globally-renowned research discoveries, and innovative educational programs. Visit ggc.org/foundation.